List today: 89bio, Inc. ETNB is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days. Altice USA ...

(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price dropped 3.7% during trading on Tuesday . The company traded as low as $7.50 and last traded at $7.50. Approximately 101,562 shares were traded during ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...

SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks 89bio ( (ETNB)) has provided an announcement. On December 12, 2024, 89bio, Inc. granted restricted stock units ...

89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate ...

89Bio, Inc. (NASDAQ:ETNB), with a market capitalization of $925 million and current share price of $7.88, is a biopharmaceutical company focused on developing therapies for liver and cardio-metabolic ...

89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 ...

SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and ...